Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.
Relief of symptoms associated with seasonal or perennial allergic rhinitis,Relief of nasal congestion,Symptomatic relief of upper respiratory tract infections
Relief of symptoms of seasonal allergic rhinitis such as sneezing, rhinorrhea, and nasal congestion,Relief of nasal congestion due to common cold or upper respiratory allergies
1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.
Dexbrompheniramine: terminal elimination half-life is approximately 12-25 hours in adults. Pseudophedrine: terminal elimination half-life is about 5-8 hours in adults with normal renal function; it is prolonged in patients with renal impairment.
Cetirizine: terminal half-life ~8.3 hours in healthy adults (prolonged to 20-30 hours in renal impairment). Pseudoephedrine: terminal half-life ~4-8 hours (p H-dependent urinary excretion; prolonged in alkaline urine).
Dexbrompheniramine is primarily metabolized by CYP3A4 and CYP2D6. Pseudoephedrine is partially metabolized by N-demethylation and oxidative deamination, with about 43-96% excreted unchanged in urine.
Cetirizine undergoes minimal hepatic metabolism via oxidation to an inactive metabolite, primarily excreted unchanged in urine. Pseudoephedrine is partially metabolized in the liver by N-demethylation to an active metabolite, with about 50-75% excreted unchanged in urine.
Dexbrompheniramine and its metabolites are primarily excreted renally (approximately 80-85% of a dose as unchanged drug and metabolites). Pseudophedrine is largely excreted unchanged in urine (70-90%) via glomerular filtration and tubular secretion; the remainder is hepatically metabolized. Biliary/fecal elimination is minimal (<5%).
Cetirizine: approximately 70% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% in feces. Pseudoephedrine: 70-90% excreted unchanged in urine; remainder as inactive metabolites.
Dexbrompheniramine: approximately 90% bound to plasma proteins. Pseudophedrine: negligible protein binding (<10%).
Cetirizine: 93% bound to albumin. Pseudoephedrine: not significantly protein bound (<10%).
Dexbrompheniramine: Vd is approximately 3-5 L/kg, indicating extensive tissue distribution. Pseudophedrine: Vd is approximately 2.5-3.5 L/kg.
Cetirizine: 0.5-0.8 L/kg (total body water). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Both components are well absorbed orally. Dexbrompheniramine: oral bioavailability is approximately 60-80%. Pseudophedrine: oral bioavailability is about 90-100%.
Cetirizine: oral bioavailability ~70% (not affected by food). Pseudoephedrine: oral bioavailability ~100% (first-pass metabolism minimal).
GFR 30-50 m L/min: extend interval to every 12-24 hours; GFR <30 m L/min: contraindicated due to risk of accumulation.
GFR 30-49 m L/min: 1 tablet every 24 hours. GFR <30 m L/min or dialysis: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Child-Pugh A or B: no dose adjustment required. Child-Pugh C: contraindicated due to lack of data.
Not recommended for children under 12 years; for ages 12+: same as adult dosing.
Children <12 years: not approved. Children ≥12 years: same as adult dosing (5 mg/120 mg every 12 hours).
Start at lowest effective dose (e.g., 1 tablet daily) due to increased sensitivity to anticholinergic effects and risk of confusion; monitor for urinary retention and hypertension.
Use with caution; start with 1 tablet every 24 hours due to increased sensitivity and risk of anticholinergic effects.
None.
None
Cardiovascular effects: hypertension, palpitations, arrhythmias; use cautiously in cardiovascular disease,CNS stimulation: nervousness, dizziness, insomnia; avoid in severe hypertension or coronary artery disease,Anticholinergic effects: urinary retention, blurred vision; caution in glaucoma or prostatic hypertrophy,Drug interactions: MAO inhibitors, sympathomimetics, antihypertensives
Cardiovascular effects: Use with caution in patients with hypertension, cardiovascular disease, or ischemic heart disease due to pseudoephedrine's vasoconstrictive and positive chronotropic effects,Cerebrovascular effects: Pseudoephedrine may cause ischemic colitis, hemorrhagic stroke, or vasospasm; avoid in patients with history of stroke or vasculopathy,Nervous system effects: May cause insomnia, nervousness, or seizure; use with caution in elderly or those with seizure disorders,Renal impairment: Dose adjustment for cetirizine necessary in moderate to severe renal impairment,Drug interactions: Avoid MAO inhibitors or use within 14 days; concomitant use with other sympathomimetics may increase adverse effects
Hypersensitivity to any component,Severe hypertension or coronary artery disease,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Narrow-angle glaucoma,Urinary retention,Severe hepatic or renal impairment
Hypersensitivity to cetirizine, pseudoephedrine, or any components,Severe hypertension or coronary artery disease,Use of monoamine oxidase inhibitors (MAOIs) currently or within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <10 m L/min) for cetirizine component
Avoid high-tyramine foods (e.g., aged cheese, cured meats, fermented products) if taking MAOIs concurrently. Pseudoephedrine's pressor effect may be enhanced by caffeine; limit caffeinated beverages.
No significant food interactions. Avoid concurrent use of caffeine or other stimulants (e.g., coffee, tea, energy drinks) as pseudoephedrine may additive CNS stimulation. Take without regard to meals; fatty meals may delay absorption of cetirizine but not clinically relevant.
First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine blood flow and cause fetal tachycardia.
Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avoid first trimester. Second/third trimester: no known fetal risks; monitor for reduced uterine blood flow due to vasoconstriction.
Probable compatibility (American Academy of Pediatrics rating). Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~3.3); may cause irritability and sleep disruption in infants. Dexbrompheniramine may suppress lactation. Consider using alternatives with lower risk.
Small amounts excreted in breast milk. M/P ratio not established for combination. Cetirizine M/P ~0.25-1.3. Pseudoephedrine M/P ~2.6-3.5; may reduce milk production. Use with caution, especially in preterm infants. Monitor infant for irritability, sleep disturbance.
No specific adjustments recommended. However, decreased gastrointestinal motility and increased plasma volume may alter absorption and distribution. Monitor clinical response.
No pharmacokinetic changes requiring routine dose adjustment in pregnancy. However, increased renal clearance may reduce cetirizine levels; clinical significance unclear. Avoid excessive pseudoephedrine due to vasoconstriction; use lowest effective dose.
Dexbrompheniramine is an alkylamine antihistamine with sedative effects; pseudoephedrine is a sympathomimetic decongestant. Avoid in severe hypertension, coronary artery disease, or MAOI use. Monitor for CNS stimulation (insomnia, nervousness) from pseudoephedrine. Antihistamines may exacerbate urinary retention in BPH or narrow-angle glaucoma. Combination therapy is common in OTC cold products.
Cetirizine/pseudoephedrine combines a second-generation antihistamine with a sympathomimetic decongestant. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in hyperthyroidism, diabetes, and prostate hyperplasia. Monitor for CNS stimulation (insomnia, nervousness) especially in evening dosing. Cetirizine is less sedating than first-generation antihistamines but may still cause drowsiness; pseudoephedrine can counteract sedation. Contraindicated with MAOIs or within 14 days of use. Not recommended in pregnancy category B (cetirizine) but pseudoephedrine crosses placenta; avoid in lactation.
Take with food or milk to reduce stomach upset.,Avoid alcohol and other CNS depressants due to additive sedation.,Do not crush or chew extended-release formulations.,Discontinue and consult prescriber if palpitations, dizziness, or tremor occur.,Not recommended for children under 6 years without prescriber approval.,Use caution when driving or operating machinery until response is known.
Take this medication by mouth with or without food, with a full glass of water.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol, as it can increase drowsiness and side effects.,May cause drowsiness or dizziness; use caution when driving or operating machinery.,Do not exceed recommended dose; do not take more than every 12 hours.,Report rapid or irregular heartbeat, chest pain, or severe dizziness.,Discontinue use and consult doctor if symptoms persist after 7 days or with fever.,Avoid taking with other cold, allergy, or sleep aids without approval.,If you have high blood pressure, heart disease, or urinary retention, consult doctor before use.,Store at room temperature, away from moisture and heat.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Dexbrompheniramine, a first-generation antihistamine with anticholinergic and sedative properties, when co-administered with guanfacine, an alpha-2 adrenergic agonist used for hypertension or ADHD, can result in additive central nervous system depression. This may lead to enhanced sedation, dizziness, impaired cognitive function, and increased risk of falls, particularly in older adults or those with compromised liver function."
"Quazepam, a benzodiazepine, and dexbrompheniramine, a first-generation antihistamine, both exhibit central nervous system (CNS) depressant effects. Their combined use can lead to additive sedation, psychomotor impairment, and respiratory depression, increasing the risk of falls, cognitive dysfunction, and excessive drowsiness. This interaction is particularly concerning in elderly patients or those with compromised respiratory function."
"Normethadone, an opioid analgesic with QT-prolonging properties, combined with cetirizine, a second-generation antihistamine that can also prolong the QT interval, increases the risk of additive cardiotoxicity, specifically potentially fatal ventricular arrhythmias like torsade de pointes. This interaction is most concerning in patients with preexisting QT prolongation, electrolyte disturbances, or those taking other QT-prolonging agents. Clinical outcomes may include palpitations, syncope, or sudden cardiac death."
"Cetirizine is a second-generation antihistamine that selectively blocks peripheral H1 receptors, while cyproheptadine is a first-generation antihistamine with additional antiserotonergic and anticholinergic properties. When coadministered, additive central nervous system depression may occur, leading to excessive sedation, dizziness, and psychomotor impairment. Concurrent use also potentiates anticholinergic adverse effects such as dry mouth, urinary retention, and blurred vision, particularly in elderly patients."
"Concurrent use of flupentixol and cetirizine may result in additive central nervous system depression, including increased sedation, drowsiness, and psychomotor impairment. Flupentixol, a thioxanthene antipsychotic with prominent antihistaminergic (H1) and antidopaminergic effects, combined with cetirizine, a peripheral H1-antihistamine with limited central penetration but dose-related sedative potential, can lead to exaggerated CNS and respiratory depression, altered cognitive function, and reduced reaction time. These effects increase the risk of falls, accidents, and respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, answered by our medical review team.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is a Sympathomimetic that works by Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is a Sympathomimetic that works by Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Sympathomimetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is: 1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.. The standard adult dose of CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is: 1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE. Combining cetirizine and dexbrompheniramine, both first-generation (dexbrompheniramine) and second-generation (cetirizine) antihistamines, leads to additive antagonism of histamine H1 receptors, potentiating central nervous system depression and anticholinergic effects. This can result in excessive sedation, dizziness, dry mouth, urinary retention, and blurred vision. Clinically, patients may experience impaired cognitive and motor function, increasing risk of falls and accidents. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is classified as Category A/B. First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine bl. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is classified as Category A/B. Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.